A new study provided by Pfizer and BioNTech firms approved the importance of the third or booster vaccine dose as it provided 95.6%, Sky News reported on Thursday.
More than 10000 participants all aged above 16 years old, and it was considered as the first study dedicated to observing the impact of the booster shots.
Both firms asserted that the study was conducted during the strong surge of the COVID-19 Delta variant in the US.
All participants received the third shot of the vaccine 11 months after being fully vaccinated. However, only five COVID-19 cases were recorded among the 10000 participants, which means that the third dose succeeded in increasing the rates of protection to more than 95%.
Albert Bourla, Chairman and Chief Executive Officer of Pfizer, said: “These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease.”
“In addition to our efforts to increase global access and uptake among the unvaccinated, we believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic. We look forward to sharing these data with health authorities and working together to determine how they can be used to support the rollout of booster doses around the world,” he highlighted.
